Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company headquartered in Petah Tikva, Israel. Founded in 1901 as a small wholesale business, Teva has grown to become one of the world's largest generic drug manufacturers and a significant player in the specialty pharmaceuticals market[1]. With operations in more than 60 countries and a portfolio of over 3,500 products, Teva plays a critical role in providing affordable medications for neurological disorders, including Parkinson's disease and Huntington's disease[2].
The company's neuroscience portfolio spans both generic and specialty medications, making it a major supplier of essential CNS treatments globally. Teva's generic versions of levodopa, pramipexole, and other Parkinson disease therapies ensure patient access to affordable treatments, while its specialty pipeline includes novel mechanisms targeting movement disorders[3].
| Attribute | Detail |
|---|---|
| Headquarters | Petah Tikva, Israel |
| Founded | 1901 |
| Ticker | TEVA (NYSE, TASE) |
| CEO | Francesco Gattrone (2024-present) |
| Employees | ~37,000 |
| Market Cap | ~$10 billion (2024) |
| Revenue (2023) | ~$16 billion |
| Focus Areas | Generic Medicines, Specialty Medicines, Over-the-Counter (OTC) |
Teva operates through three main divisions:
Teva has a significant presence in the central nervous system (CNS) space through both generic and specialty medications that address movement disorders, migraine, and other neurological conditions[4].
Teva manufactures generic versions of many important CNS drugs, ensuring broad patient access to essential neurological medications[5]:
| Drug | Brand Equivalent | Indication |
|---|---|---|
| Levodopa/Carbidopa | Sinemet | Parkinson's disease |
| Pramipexole | Mirapex | Parkinson's disease |
| Ropinirole | Requip | Parkinson's disease |
| Gabapentin | Neurontin | Epilepsy, neuropathic pain |
| Pregabalin | Lyrica | Epilepsy, neuropathic pain |
| Sertraline | Zoloft | Depression |
| Escitalopram | Lexapro | Depression |
| Quetiapine | Seroquel | Schizophrenia |
| Aripiprazole | Abilify | Schizophrenia, bipolar |
| Clonazepam | Klonopin | Seizures, anxiety |
The generic levodopa/carbidopa combination remains the gold standard for Parkinson's disease treatment, and Teva's generic versions ensure this essential therapy remains affordable and accessible globally[6].
Teva's specialty pipeline focuses on novel mechanisms for unmet needs in movement disorders and migraine[7]:
| Drug | Brand Name | Indication | Mechanism | Status |
|---|---|---|---|---|
| Deutetrabenazine | Austedo | Huntington's disease chorea | VMAT2 inhibitor | Approved (2017) |
| Deutetrabenazine | SD-809 | Tardive dyskinesia | VMAT2 inhibitor | Approved (2023) |
| Fremanezumab | Ajovy | Migraine prevention | CGRP monoclonal antibody | Approved (2018) |
| TEV-247 | — | Parkinson's disease | A2A adenosine receptor antagonist | Phase 2 |
| TEV-385 | — | ALS | SOD1 antisense oligonucleotide | Phase 1 |
Deutetrabenazine represents a significant advancement in the treatment of hyperkinetic movement disorders. This novel formulation uses deuterium-substituted tetrabenazine to improve pharmacokinetics and reduce dosing frequency while maintaining efficacy[7:1].
Deutetrabenazine works by reversibly inhibiting VMAT2 (vesicular monoamine transporter 2), which is responsible for packaging monoamines—including dopamine—into synaptic vesicles. In conditions like Huntington's disease and tardive dyskinesia, excessive dopaminergic signaling in the striatum leads to involuntary movements. By modulating VMAT2, deutetrabenazine reduces available dopamine without causing complete depletion[8].
The deuterium substitution provides several advantages:
The KARMMA trials demonstrated:
Fremanezumab is a fully humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), a key neuropeptide involved in migraine pathophysiology[9].
CGRP is a potent vasodilator and neurotransmitter released from trigeminal nerve endings. In migraine, CGRP levels correlate with pain intensity. Anti-CGRP antibodies like fremanezumab represent a targeted approach without the cardiovascular side effects of older preventive medications.
TEV-247 is in Phase 2 development for Parkinson's disease. Adenosine A2A receptors are highly expressed in the basal ganglia, particularly in the striatum, where they modulate dopaminergic signaling. A2A antagonists like istradefylline (Nourianz) have shown efficacy as adjunct therapy to levodopa.
Rationale: A2A antagonists may provide:
TEV-385 is an antisense oligonucleotide targeting SOD1 mutations that cause approximately 20% of familial ALS. Similar to the FDA-approved tofersen (Qalsody), this approach aims to reduce mutant SOD1 protein production.
Teva maintains strategic partnerships to enhance its neuroscience capabilities:
| Partner | Focus Area | Details |
|---|---|---|
| Almirall | Dermatology | Multi-product collaboration |
| Lonza | Manufacturing | Biologics manufacturing |
| MediGene | CNS pipeline | Development partnerships |
| Various academic institutions | Research | Clinical trial collaborations |
Teva occupies a unique position in the pharmaceutical landscape:
Generic Leadership: Teva is the #1 generic pharmaceutical company globally, with significant market share in:
Specialty Competition: In specialty CNS, Teva competes with:
Teva's contributions to neurodegenerative disease care are substantial:
Teva's neuroscience products represent a significant portion of specialty revenue:
The company's debt reduction efforts and focus on specialty pharmaceuticals have improved profitability since the 2018 Actavis integration.
Teva's neuroscience strategy focuses on:
Kalia LV et al. Parkinson disease: advances in pathogenesis and treatment. Lancet. 2021. ↩︎
Schapira AHV et al. Parkinson's disease and generic drugs: The impact on patient outcomes. Movement Disorders. 2021. ↩︎
Poewe W et al. Levodopa in Parkinson's disease. Lancet. 2020. ↩︎
Fernandez et al. Deutetrabenazine for chorea in Huntington disease: A randomized controlled trial. Neurology. 2016. ↩︎ ↩︎ ↩︎
J. et al. VMAT2 inhibitors and the pathogenesis of parkinsonism. Annals of Neurology. 2022. ↩︎
Khan et al. Calcitonin gene-related peptide monoclonal antibodies for migraine prevention. Headache. 2019. ↩︎